|
Indications and Dosage
Topical/Cutaneous
Corticosteroid-responsive dermatoses Adult: As 0.05% ointment/cream: Apply thinly and rub gently onto the affected area once daily or bid, gradually discontinue once control is achieved. Max treatment duration: 4 weeks.
Child: Same as adult dose. Max treatment duration: 7 days. |
|
Contraindications
Untreated cutaneous infections of bacterial, fungal, treponemal, tuberculous, or viral origin; acne vulgaris, pruritus without inflammation, perioral dermatitis, rosacea.
|
|
Special Precautions
Patient with psoriasis, stasis dermatitis. Not recommended for long-term use (particularly on the face). Children and elderly. Pregnancy and lactation.
|
|
Adverse Reactions
Significant: HPA axis suppression (e.g. Cushingoid features, hyperglycaemia, glycosuria), allergic contact dermatitis, bacterial or fungal superinfection, increased risk of posterior subscapular cataracts and glaucoma.
Eye disorders: Blurred vision, visual disturbance. Skin and subcutaneous tissue disorders: Pruritus. |
|
Patient Counseling Information
Avoid application to the face, scalp, groin, genitals, axilla, or between toes without medical advice. Avoid contact with eyes. Do not use occlusive dressing. Avoid abrupt withdrawal.
|
|
Monitoring Parameters
Monitor for adrenal insufficiency and HPA axis suppression. Assess for signs and symptoms of visual disturbances.
|
|
Overdosage
Symptoms: Hypercortisolism or Cushing’s syndrome (e.g. moon face, buffalo hump, hirsutism, weight gain), and HPA axis suppression. Management: Withdraw clobetasone gradually by decreasing the frequency of application or use less potent corticosteroids.
|
|
Drug Interactions
Increased systemic exposure with CYP3A4 inhibitors (e.g. ritonavir, itraconazole).
|
|
Action
Description:
Mechanism of Action: Clobetasone is a moderately potent corticosteroid with anti-inflammatory, antipruritic and vasoconstrictive properties. It induces phospholipase A2 inhibitory proteins (lipocortins) thereby depressing the formation, release, and activity of endogenous chemical mediators of inflammation (e.g. histamine, kinase, liposomal enzymes, prostaglandins). It also decreases the density of mast cells, chemotaxis, activation of eosinophils, and cytokine production, and inhibits the metabolism of arachidonic acid. Pharmacokinetics: Absorption: May be systematically absorbed from intact healthy skin. Metabolism: Metabolised in the liver. Excretion: Via urine and bile. |
|
Chemical Structure
 Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 71387, Clobetasone. https://pubchem.ncbi.nlm.nih.gov/compound/Clobetasone. Accessed Oct. 25, 2023. |
|
Storage
Store between 15-30°C. Protect from light.
|
|
MIMS Class
|
|
ATC Classification
D07AB01 - clobetasone ; Belongs to the class of moderately potent (group II) corticosteroids. Used in the treatment of dermatological diseases.
|
|
References
Anon. Clobetasone. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 13/04/2023. Buckingham R (ed). Clobetasone Butyrate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 13/04/2023. Clobavate 0.05% w/w Ointment (Teva UK Limited). MHRA. https://products.mhra.gov.uk. Accessed 13/04/2023. Eumovate Cream (Glaxo Wellcome UK Ltd.). MHRA. https://products.mhra.gov.uk. Accessed 13/04/2023. GlaxoSmithKline NZ Limited. Eumovate 0.05% w/w Cream data sheet 17 August 2020. Medsafe. http://www.medsafe.govt.nz. Accessed 13/04/2023. Joint Formulary Committee. Clobetasone Butyrate. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 13/04/2023. U-Closone Cream and Ointment (HOE Pharmaceuticals Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 13/04/2023.
|
Sign Out
